Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
316. |
ECCT/13/03/02 | An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples An open-label, pilot demonstration and evaluation project of antiretroviral-based HIV-1 prevention among high-risk HIV-1 serodiscordant African couples The Partners PrEP Study Demonstration Project |
Principal Investigator(s) 1. DR.ELIZABETH ANNE BUKUSI ELIZABETH ANNE BUKUSI Site(s) in Kenya 1. THIKA (Nairobi City county) |
View |
317. |
ECCT/13/04/03 | HIV-Malaria Study_A5297 An Open-Label, Proof of Concept, Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Plasmodium falciparum Subclinical Parasitemia in HIV-infected Adults with CD4+ Counts >200 and <350 cells/mm3 . |
Principal Investigator(s) 1. Josphat K. Kosgei Site(s) in Kenya 1. Kemri Walter Reed Project-Kericho (Kericho county) 2. Moi University Clinical Research Centre (Uasin Gishu county) |
View |
318. |
ECCT/20/10/04 | yellow fever vaccine CVIA 079 A Phase III double-blind, randomized, active comparator controlled study in healthy Kenyan adolescents, young children and infants to assess the safety and immunogenicity of Beijing Institute of Biologic Products (BIBP) yellow fever vaccine in comparison to a WHO 17D-204 prequalified comparator yellow fever vaccine, as well as lot-to-lot consistency of immune response to the BIBP yellow fever vaccine”, CVIA 079. |
Principal Investigator(s) 1. Dr. Deborah Langat Site(s) in Kenya KEMRI/KERICHO CLINIC RESEARCH CENTRE |
View |
319. |
ECCT/14/03/02 | Rivaroxaban on prevention of stroke and non-central nervous system systemic embolism in patients with non valvular atrial fibrillation XANTUS-EL, Xarelto on prevention of stroke and non-central nervous system systemic embolism in patients with non valvular atrial fibrillation - a non interventional study, XA 1206 (IMPACT No. 16691) |
Principal Investigator(s) 1. Warshow Majid Mbarak Site(s) in Kenya 1. MP Shah Hospital (Nairobi City county) |
View |
320. |
ECCT/22/08/02 | AIM-LVRNA009-II_III-01 A Global Multi-center, Randomized, Blinded, Placebo-controlled Phase 2/3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (LVRNA009) for the Prevention of COVID-19 in Participants Aged 18 Years and Olde |
Principal Investigator(s) 1. Bernhards Ogutu 2. Lucas Otieno 3. Videlis Nduba 4. Bernhards Ogutu 5. Jacqueline Mirera 6. Jacqueline Mirera Site(s) in Kenya 1. Siaya Clinical Trials Unit (Siaya county) 2. Homa Bay Clinical Trials Unit (Homa Bay county) 3. Ahero Clinical Trials Unit (Kisumu county) 4. CREA-N Machakos (Machakos county) 5. CREA-N Nakuru (Nakuru county) 6. Victoria Biomedical Research Institue (Kisumu county) |
View |